» Articles » PMID: 32368293

MicroRNA Expression Profiling in Young Prostate Cancer Patients

Overview
Journal J Cancer
Specialty Oncology
Date 2020 May 6
PMID 32368293
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) are small, non-coding RNA molecules with multiple roles in many biological processes. Few studies have shown the molecular characteristics in younger prostate cancer (PCa) patients. In this study, we performed miRNA profiling in young PCa (EO-PCa) cases compared with PCa arising in older men (LO-PCa). : Formalin-fixed, paraffin embedded tissue was used. miRNA was extracted for PCR array and NanoString methods. Relative miRNAs expression levels were obtained by comparing young vs older men, and young PCa tumor samples vs normal epithelium. : miRNA profiling showed a different expression pattern in PCa arising in younger men, and young PCa tumoral and its normal counterpart. Nine miRNAs (hsa-miR-140-5p, hsa-miR-146a, hsa-miR-29b, hsa-miR-9, hsa-miR-124-3p, hsa-let-7f-5p, hsa-miR-184, hsa-miR-373, hsa-miR-146b-5p) showed differences in the expression compared to LO-PCa. Fourteen miRNAs were significantly up-regulated (miR-1973, miR-663a, miR-575, miR-93-5p, miR-630, miR-600, miR-494, miR-150-5p, miR-137, miR-25-3p, miR-375, miR-489, miR-888-5p, miR-142-3p), while 9 were found down-regulated (miR-21-5p, miR-363-3p, miR-205-5p, miR-548ai, miR-3195, 145-5p, miR-143-3p, miR-222-3p, miR-221-3p) comparing young PCa tumoral tissue compared to normal counterpart. The higher expression of miR-600 and miR-137 were associated with high Gleason score, extraprostatic extension and lymphatic invasion. : These results suggest that PCa in younger patients has a different expression profile compared to normal tissue and PCa arising in older man. Differentially expressed miRNAs provide insights of molecular mechanisms involve in this PCa subtype.

Citing Articles

hsa-mir-483-3p modulates delayed breast cancer recurrence.

Kim O, Jeon T, Kang H, Chang E, Hong S, Kim M Sci Rep. 2025; 15(1):693.

PMID: 39753688 PMC: 11698896. DOI: 10.1038/s41598-024-84437-6.


The role of CEMIP in cancers and its transcriptional and post-transcriptional regulation.

Guo S, Guo Y, Chen Y, Cui S, Zhang C, Chen D PeerJ. 2024; 12:e16930.

PMID: 38390387 PMC: 10883155. DOI: 10.7717/peerj.16930.


Microfluidic-based prostate cancer model for investigating the secretion of prostate-specific antigen and microRNAs in vitro.

Padmyastuti A, Sarmiento M, Dib M, Ehrhardt J, Schoon J, Somova M Sci Rep. 2023; 13(1):11623.

PMID: 37468746 PMC: 10356943. DOI: 10.1038/s41598-023-38834-y.


Smoking-related dysregulation of plasma circulating microRNAs: the Rotterdam study.

Karabegovic I, Maas S, Shuai Y, Ikram M, Stricker B, Aerts J Hum Genomics. 2023; 17(1):61.

PMID: 37430296 PMC: 10331979. DOI: 10.1186/s40246-023-00504-5.


MicroRNAs as clinical tools for diagnosis, prognosis, and therapy in prostate cancer.

Ghamlouche F, Yehya A, Zeid Y, Fakhereddine H, Fawaz J, Liu Y Transl Oncol. 2023; 28:101613.

PMID: 36608541 PMC: 9827391. DOI: 10.1016/j.tranon.2022.101613.


References
1.
Nilsson E, Laursen K, Whitchurch J, McWilliam A, Odum N, Persson J . MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators. Oncotarget. 2015; 6(34):35710-25. PMC: 4742136. DOI: 10.18632/oncotarget.5958. View

2.
Li X, Kong X, Wang Y, Yang Q . BRCC2 inhibits breast cancer cell growth and metastasis in vitro and in vivo via downregulating AKT pathway. Cell Death Dis. 2013; 4:e757. PMC: 3763451. DOI: 10.1038/cddis.2013.290. View

3.
Wu D, Wang Y, Wang L, Chen C, Lee H . A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. Theranostics. 2018; 8(5):1256-1269. PMC: 5835934. DOI: 10.7150/thno.22048. View

4.
Chen W, Zhang Z, Ding Z, Liang H, Song J, Tan X . MicroRNA-630 suppresses tumor metastasis through the TGF-β- miR-630-Slug signaling pathway and correlates inversely with poor prognosis in hepatocellular carcinoma. Oncotarget. 2016; 7(16):22674-86. PMC: 5008391. DOI: 10.18632/oncotarget.8047. View

5.
Zhao J, Chen P, Duan R, Li K, Wang Y, Li Y . miR-630 functions as a tumor oncogene in renal cell carcinoma. Arch Med Sci. 2016; 12(3):473-8. PMC: 4889681. DOI: 10.5114/aoms.2016.59918. View